site in Beuvry-la-Forêt in northern France . This should be ready for qualification by mid-2023 , said general manager Sebastien Poncet . It will feature a high level of automation and computer control . In addition , Minakem is investing about € 15 million in high potency HPLC to support HPAPI projects .
Award winners
Also featuring in the CPHI Pharma Awards alongside Aragen was Lonza Capsules & Health Ingredients . It won in the Regulatory Procedures & Compliance category for its Capsugel
TiO 2
-free white gelatin capsule for intestinal drug delivery , which was launched at the show .
This is an opacifying technology that uses the functionality of crystallised salts to provide the same whiteness and masking as capsules containing
TiO 2
, which faces increasing restrictions in the EU . The capsule remains intact during stomach transit and only releases its contents in the intestine , while simplifying drug product manufacturing by avoiding the need for additional capsule coating or sealing .
Lonza also announced an agreement under which it will gain access to Singzyme ’ s enzymatic conjugation platform for site-specific binding of payloads with peptidic linkers to proteins of interest . This , said Stefan Egli , head of bioconjugates ,
“ represents an attractive addition to Lonza ’ s bioconjugation toolbox ”. Evonik , meanwhile , won the Pharmaceutical Packaging & Drug Delivery award for its polymeric nucleic acid delivery systems . These comprise a new class of polymers that complement existing lipid nanoparticle-based delivery technologies .
The company has also entered into a long-term agreement under which it will supply large-scale volumes of vonoprazan from sites in the US and Germany to Phathom Pharmaceuticals , a US biopharma company focused on gastric acid-related diseases . Evonik used its expertise in heterogeneous catalysis to achieving high purity in the API used in vonoprazan .
Further announcements
In the week before the show , Curia hosted a groundbreaking ceremony to mark the beginning of construction of its expanded campus in Albuquerque , New Mexico . The additional space will house an isolated high-speed fill-finish vial line – which includes biosafety level 2 ( BSL-2 ) containment , two lyophilisers for the high-speed fill-finish line and an isolated flexible
Groundbreaking at Curia ’ s expanded facility
filling line for vials , syringes and cartridges to support smaller-batch advanced therapies .
Similarly , Cambrex had announced that it is investing in a 1,950 m 2 facility near Minneapolis – St . Paul Airport . This will specialise in analytical and chemical development for small molecule drug candidates . A multiphase , 835 m 2 expansion and a 1,950 m 2 renovation project are also ongoing at the flagship site in Charles City , Iowa , which will add a QC laboratory and administrative office space .
In response to increasing demand in the later stages of development , EuroAPI announced an initial € 18 million investment in manufacturing capacity for peptides and oligonucleotides at its Frankfurt site as part of a multi-stage effort . The aim is to debottleneck current capacity and increase output to about 500 kg / year by 2025 , without the need for any downtime .
Also in the peptide field , AmbioPharm announced a strategic partnership to supply of peptide conjugates to Ariceum for use in future clinical studies . Ariceum is based in Berlin and develops radiopharmaceutical products for the diagnosis and systemic targeted radiation therapy of certain hardto-treat cancers .
In the run-up to CPHI Frankfurt , Dipharma Francis announced that the Italian Medicines Agency , AIFA , has approved its new production line at the cGMP pilot plant suite in Mereto
54 SPECIALITY CHEMICALS MAGAZINE ESTABLISHED 1981